FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

	-								-	
N۵	as	hi	nai	ton	. D	.C.	. 2	054	19	

STATEMENT	OF	CHANGES	IN BEI	NEFICIAL	OWNERSH	ΙP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HANNAH ALISON L. (Last) (First) (Middle) C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., STE. 400 (Street) SOUTH SAN CA 94080					Issuer Name and Ticker or Trading Symbol CytomX Therapeutics, Inc. [CTMX] Date of Earliest Transaction (Month/Day/Year) 10/24/2021 A. If Amendment, Date of Original Filed (Month/Day/Year)					6. Inc	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Medical Officer 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(City)	ty) (State) (Zip)											Form filed by More than One Reporting Person				
Title of Security (Instr. 3) 2. Transa Date (Month/D) Table II - Derivat					ay/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) 5)			4. Securit Disposed 5) Amount	(A) or (D) Price		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
1. Title of Derivative Conversion Security Or Exercise (Month/Day/Year) if any		4. Transa	1. 5. Number of Oracle (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownershi Form: y Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$5.34	10/24/2021		A		40,000		(1)	10/23/2031	Common Stock	40,000	\$0.00	40,000	D		
Performance Stock Units (PSUs)	(2)	10/24/2021		A		30,000		(2)	(2)	Common Stock	30,000	\$0.00	30,000	D		

- 1. 1/48th of the shares subject to the option vest on each monthly anniversary measured from October 24, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
- 2. Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date.

/s/ Lloyd Rowland, as Attorney-10/26/2021 in-Fact for Alison L. Hannah

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.